Biogen Inc. (ETR:IDP)
113.35
+3.30 (3.00%)
May 27, 2025, 5:35 PM CET
Biogen Revenue
Biogen had revenue of $2.43B USD in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
1.79
Revenue / Employee
$1.29M
Employees
7,605
Market Cap
16.26B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Biogen News
- 11 hours ago - Biogen and City Therapeutics partner to develop RNAi therapies - Seeking Alpha
- 15 hours ago - Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies - GlobeNewsWire
- 5 days ago - Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen - Seeking Alpha
- 15 days ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 15 days ago - Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal - GlobeNewsWire
- 25 days ago - Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
- 26 days ago - Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact - Benzinga
- 26 days ago - Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025 - Seeking Alpha